151 related articles for article (PubMed ID: 37641480)
21. The First Iranian Cohort of Pediatric Patients with Activated Phosphoinositide 3-Kinase-δ (PI3Kδ) Syndrome (APDS).
Fekrvand S; Delavari S; Chavoshzadeh Z; Sherkat R; Mahdaviani SA; Sadeghi Shabestari M; Azizi G; Arzanian MT; Shahin Shamsian B; Eskandarzadeh S; Eslami N; Rae W; Condino-Neto A; Mohammadi J; Abolhassani H; Yazdani R; Aghamohammadi A
Immunol Invest; 2022 Apr; 51(3):644-659. PubMed ID: 33401995
[TBL] [Abstract][Full Text] [Related]
22. Molecular and Functional Characterization of Three Different Postzygotic Mutations in PIK3CA-Related Overgrowth Spectrum (PROS) Patients: Effects on PI3K/AKT/mTOR Signaling and Sensitivity to PIK3 Inhibitors.
Loconte DC; Grossi V; Bozzao C; Forte G; Bagnulo R; Stella A; Lastella P; Cutrone M; Benedicenti F; Susca FC; Patruno M; Varvara D; Germani A; Chessa L; Laforgia N; Tenconi R; Simone C; Resta N
PLoS One; 2015; 10(4):e0123092. PubMed ID: 25915946
[TBL] [Abstract][Full Text] [Related]
23. Megalencephaly syndromes and activating mutations in the PI3K-AKT pathway: MPPH and MCAP.
Mirzaa GM; Rivière JB; Dobyns WB
Am J Med Genet C Semin Med Genet; 2013 May; 163C(2):122-30. PubMed ID: 23592320
[TBL] [Abstract][Full Text] [Related]
24. Constitutive activation of the PI3K-AKT pathway and cardiovascular abnormalities in an individual with Kosaki overgrowth syndrome.
Zarate YA; Boccuto L; Srikanth S; Pauly R; Ocal E; Balmakund T; Hinkle K; Stefans V; Schaefer GB; Collins RT
Am J Med Genet A; 2019 Jun; 179(6):1047-1052. PubMed ID: 30941910
[TBL] [Abstract][Full Text] [Related]
25. In vitro efficacy of ARQ 092, an allosteric AKT inhibitor, on primary fibroblast cells derived from patients with PIK3CA-related overgrowth spectrum (PROS).
Ranieri C; Di Tommaso S; Loconte DC; Grossi V; Sanese P; Bagnulo R; Susca FC; Forte G; Peserico A; De Luisi A; Bartuli A; Selicorni A; Melis D; Lerone M; Praticò AD; Abbadessa G; Yu Y; Schwartz B; Ruggieri M; Simone C; Resta N
Neurogenetics; 2018 May; 19(2):77-91. PubMed ID: 29549527
[TBL] [Abstract][Full Text] [Related]
26. Vascular malformations syndromes: an update.
Martinez-Lopez A; Salvador-Rodriguez L; Montero-Vilchez T; Molina-Leyva A; Tercedor-Sanchez J; Arias-Santiago S
Curr Opin Pediatr; 2019 Dec; 31(6):747-753. PubMed ID: 31693582
[TBL] [Abstract][Full Text] [Related]
27. The somatic p.T81dup variant in AKT3 gene underlies a mild cerebral phenotype and expands the spectrum including capillary malformation and lateralized overgrowth.
Luca M; Piglionica M; Bagnulo R; Cardaropoli S; Carli D; Turchiano A; Coppo P; Pantaleo A; Iacoviello M; Ferrero GB; Mussa A; Resta N
Genes Chromosomes Cancer; 2023 Dec; 62(12):703-709. PubMed ID: 37395289
[TBL] [Abstract][Full Text] [Related]
28. Clinical and functional characterization of germline PIK3CA variants in patients with PIK3CA-related overgrowth spectrum disorders.
Cooley Coleman JA; Gass JM; Srikanth S; Pauly R; Ziats CA; Everman DB; Skinner SA; Bell S; Louie RJ; Cascio L; Patterson WG; Jones JR; Di Donato N; Stevenson RE; Boccuto L
Hum Mol Genet; 2023 Apr; 32(9):1457-1465. PubMed ID: 36458889
[TBL] [Abstract][Full Text] [Related]
29. Somatic loss of PIK3R1 may sensitize breast cancer to inhibitors of the MAPK pathway.
Turturro SB; Najor MS; Yung T; Portt L; Malarkey CS; Abukhdeir AM; Cobleigh MA
Breast Cancer Res Treat; 2019 Sep; 177(2):325-333. PubMed ID: 31209687
[TBL] [Abstract][Full Text] [Related]
30. [Clinical and immunological characteristics of a case with activated phosphoinositide 3-kinase δ syndrome 2].
Yang QY; Jia YJ; Wang YP; Zeng T; Zhao XD; Zhou LN
Zhonghua Er Ke Za Zhi; 2020 May; 58(5):413-417. PubMed ID: 32392959
[No Abstract] [Full Text] [Related]
31. Human PIK3R1 mutations disrupt lymphocyte differentiation to cause activated PI3Kδ syndrome 2.
Nguyen T; Lau A; Bier J; Cooke KC; Lenthall H; Ruiz-Diaz S; Avery DT; Brigden H; Zahra D; Sewell WA; Droney L; Okada S; Asano T; Abolhassani H; Chavoshzadeh Z; Abraham RS; Rajapakse N; Klee EW; Church JA; Williams A; Wong M; Burkhart C; Uzel G; Croucher DR; James DE; Ma CS; Brink R; Tangye SG; Deenick EK
J Exp Med; 2023 Jun; 220(6):. PubMed ID: 36943234
[TBL] [Abstract][Full Text] [Related]
32. The effect of rapamycin, NVP-BEZ235, aspirin, and metformin on PI3K/AKT/mTOR signaling pathway of PIK3CA-related overgrowth spectrum (PROS).
Suzuki Y; Enokido Y; Yamada K; Inaba M; Kuwata K; Hanada N; Morishita T; Mizuno S; Wakamatsu N
Oncotarget; 2017 Jul; 8(28):45470-45483. PubMed ID: 28525374
[TBL] [Abstract][Full Text] [Related]
33. miR-100-3p inhibits the adipogenic differentiation of hMSCs by targeting PIK3R1 via the PI3K/AKT signaling pathway.
Wang T; Zhong D; Qin Z; He S; Gong Y; Li W; Li X
Aging (Albany NY); 2020 Nov; 12(24):25090-25100. PubMed ID: 33221758
[TBL] [Abstract][Full Text] [Related]
34. The Role of PIK3R1 in Metabolic Function and Insulin Sensitivity.
Tsay A; Wang JC
Int J Mol Sci; 2023 Aug; 24(16):. PubMed ID: 37628845
[TBL] [Abstract][Full Text] [Related]
35. Epilepsy with faint capillary malformation or reticulated telangiectasia associated with mosaic AKT3 pathogenic variants.
De Bortoli M; Ivars M; Revencu N; Nassogne MC; Lavarino C; Paco S; Lammens M; Renders A; Dumitriu D; Helaers R; Boon LM; Baselga E; Vikkula M
Am J Med Genet A; 2024 Jun; 194(6):e63551. PubMed ID: 38321651
[TBL] [Abstract][Full Text] [Related]
36. Enhanced AKT Phosphorylation of Circulating B Cells in Patients With Activated PI3Kδ Syndrome.
Asano T; Okada S; Tsumura M; Yeh TW; Mitsui-Sekinaka K; Tsujita Y; Ichinose Y; Shimada A; Hashimoto K; Wada T; Imai K; Ohara O; Morio T; Nonoyama S; Kobayashi M
Front Immunol; 2018; 9():568. PubMed ID: 29675019
[TBL] [Abstract][Full Text] [Related]
37. MiR-155 promotes interleukin-1β-induced chondrocyte apoptosis and catabolic activity by targeting PIK3R1-mediated PI3K/Akt pathway.
Fan Z; Liu Y; Shi Z; Deng K; Zhang H; Li Q; Cao S; Li S; Zhang H
J Cell Mol Med; 2020 Aug; 24(15):8441-8451. PubMed ID: 32562373
[TBL] [Abstract][Full Text] [Related]
38. PIK3R1 underexpression is an independent prognostic marker in breast cancer.
Cizkova M; Vacher S; Meseure D; Trassard M; Susini A; Mlcuchova D; Callens C; Rouleau E; Spyratos F; Lidereau R; Bièche I
BMC Cancer; 2013 Nov; 13():545. PubMed ID: 24229379
[TBL] [Abstract][Full Text] [Related]
39.
Pagliazzi A; Oranges T; Traficante G; Trapani C; Facchini F; Martin A; Semeraro A; Perrone A; Filippeschi C; Giglio S
Front Pediatr; 2021; 9():732836. PubMed ID: 34568242
[No Abstract] [Full Text] [Related]
40. Phenotypic and molecular characterization of five patients with PIK3CA-related overgrowth spectrum (PROS).
Gökpınar İli E; Taşdelen E; Durmaz CD; Altıner Ş; Tuncalı T; Martinez-Glez V; Karabulut HG; Vural S; Ceylaner S; Acar MO; Ilgın Ruhi H
Am J Med Genet A; 2022 Jun; 188(6):1792-1800. PubMed ID: 35238469
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
